Haselbeck Andrea H, Panzner Ursula, Im Justin, Baker Stephen, Meyer Christian G, Marks Florian
aInternational Vaccine Institute, Epidemiology Unit, Seoul, Republic of Korea bHospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam cDepartment of Medicine, University of Cambridge, Cambridge, United Kingdom dInstitute of Tropical Medicine, Eberhard-Karls University Tübingen, Tübingen, Germany eDuy Tan University, Da Nang, Vietnam *Andrea H. Haselbeck and Ursula Panzner contributed equally to the writing of this article.
Curr Opin Infect Dis. 2017 Oct;30(5):498-503. doi: 10.1097/QCO.0000000000000398.
We searched PubMed for scientific literature published in the past 2 years for relevant information regarding the burden of invasive nontyphoidal Salmonella disease and host factors associated with nontyphoidal Salmonella infection and discuss current knowledge on vaccine development. The following search terms were used: Salmonella, non typhoidal/nontyphoidal, NTS, disease, bloodstream infection, invasive, sepsis/septicaemia/septicemia, bacteraemia/bacteremia, gastroenteritis, incidence, prevalence, morbidity, mortality, case fatality, host/risk factor, vaccination, and prevention/control.
Estimates of the global invasive nontyphoidal Salmonella disease burden have been recently updated; additional data from Africa, Asia, and Latin America are now available. New data bridge various knowledge gaps, particularly with respect to host risk factors and the geographical distribution of iNTS serovars. It has also been observed that Salmonella Typhimurium sequence type 313 is emergent in several African countries. Available data suggest that genetic variation in the sequence type 313 strain has led to increased pathogenicity and human host adaptation. A bivalent efficacious vaccine, targeting Salmonella serovars Typhimurium and Enteritidis, would significantly lower the disease burden in high-risk populations.
The mobilization of surveillance networks, especially in Asia and Latin America, may provide missing data regarding the invasive nontyphoidal Salmonella disease burden and their corresponding antimicrobial susceptibility profiles. Efforts and resources should be directed toward invasive nontyphoidal Salmonella disease vaccine development.
我们在PubMed上搜索了过去两年发表的科学文献，以获取有关侵袭性非伤寒沙门氏菌病负担以及与非伤寒沙门氏菌感染相关的宿主因素的相关信息，并讨论目前关于疫苗开发的知识。使用了以下检索词：沙门氏菌、非伤寒/非伤寒性、NTS、疾病、血流感染、侵袭性、败血症/脓毒症/败血病、菌血症、肠胃炎、发病率、患病率、发病率、死亡率、病死率、宿主/危险因素、疫苗接种以及预防/控制。
全球侵袭性非伤寒沙门氏菌病负担的估计值最近得到了更新；现在有来自非洲、亚洲和拉丁美洲的更多数据。新数据填补了各种知识空白，特别是在宿主危险因素和侵袭性非伤寒沙门氏菌血清型的地理分布方面。还观察到鼠伤寒沙门氏菌序列型313在几个非洲国家出现。现有数据表明，序列型313菌株的基因变异导致了致病性增加和对人类宿主的适应性增强。一种针对鼠伤寒沙门氏菌和肠炎沙门氏菌血清型的二价有效疫苗将显著降低高危人群的疾病负担。
尤其是在亚洲和拉丁美洲，调动监测网络可能会提供有关侵袭性非伤寒沙门氏菌病负担及其相应抗菌药物敏感性概况的缺失数据。应将努力和资源导向侵袭性非伤寒沙门氏菌病疫苗的开发。
